

D1
sub E1 >
Claim 39 (Twice amended). A recombinantly produced *H. pylori* CT polypeptide, wherein the recombinantly produced polypeptide (i) comprises at least ten amino acids, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits substantially no toxicity, or substantially reduced toxicity.

Claim 40 (Twice amended). A recombinantly produced *H. pylori* CT polypeptide comprising SEQ ID NO:3 or a fragment thereof, which polypeptide or fragment thereof: (i) comprises at least ten amino acids of SEQ ID NO:3, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits substantially no toxicity, or substantially reduced toxicity.

Claim 42 (Twice amended). The polypeptide of either of claims 39 or 40, wherein said polypeptide comprises at least fifteen amino acids.

D2
Claim 43 (Twice amended). A prophylactic or therapeutic vaccine comprising an immunologically effective amount of a *H. pylori* CT polypeptide comprising SEQ ID NO:3 or a fragment thereof, which polypeptide: (i) comprises at least ten amino acids of SEQ ID NO:3, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits substantially no toxicity, or substantially reduced toxicity.

D3
Claim 45 (Twice amended). The vaccine of claim 43, wherein said polypeptide comprises at least fifteen amino acids.

D3
cont.

Claim 46 (Twice amended). The vaccine of claim 43, further comprising an immunologically effective amount of a second polypeptide comprising *H. pylori* cytotoxin associated immunodominant (CAI) antigen or a fragment thereof, which second polypeptide: (i) comprises at least ten amino acids, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits no functional contribution to toxicity, or a substantially reduced functional contribution to toxicity.

Claim 48 (Twice amended). The vaccine of claim 46, wherein said second polypeptide comprises at least fifteen amino acids.

Claim 49 (Twice amended). A method of preparing a prophylactic or therapeutic vaccine comprising bringing into association:

- D4
- (1) an immunologically effective amount of a *H. pylori* CT polypeptide, which polypeptide: (i) comprises at least ten amino acids, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits substantially no toxicity, or substantially reduced toxicity, and
 - (2) a pharmaceutically acceptable carrier.

Claim 50 (Twice amended). The method of claim 49, further comprising adding an immunologically effective amount of a second polypeptide comprising *H. pylori* CAI antigen or fragment thereof, which second polypeptide: (i) comprises at least ten amino acids, (ii) can induce the production of antibodies to *H. pylori*, and (iii) exhibits no functional contribution to toxicity, or a substantially reduced functional contribution to toxicity.